Search Results
Search for other papers by G Rindi in
Google Scholar
PubMed
Search for other papers by C Klersy in
Google Scholar
PubMed
Search for other papers by F Inzani in
Google Scholar
PubMed
Search for other papers by G Fellegara in
Google Scholar
PubMed
Search for other papers by L Ampollini in
Google Scholar
PubMed
Search for other papers by A Ardizzoni in
Google Scholar
PubMed
Search for other papers by N Campanini in
Google Scholar
PubMed
Search for other papers by P Carbognani in
Google Scholar
PubMed
Search for other papers by T M De Pas in
Google Scholar
PubMed
Search for other papers by D Galetta in
Google Scholar
PubMed
Search for other papers by P L Granone in
Google Scholar
PubMed
Search for other papers by L Righi in
Google Scholar
PubMed
Search for other papers by M Rusca in
Google Scholar
PubMed
Search for other papers by L Spaggiari in
Google Scholar
PubMed
Search for other papers by M Tiseo in
Google Scholar
PubMed
Search for other papers by G Viale in
Google Scholar
PubMed
Search for other papers by M Volante in
Google Scholar
PubMed
Search for other papers by M Papotti in
Google Scholar
PubMed
Institute of Anatomic Pathology, Service of Biometry and Clinical Epidemiology, Service of Pathology, Thoracic Unit, Medical Oncology Unit, Unit of Pathological Anatomy, Medical Oncology Unit of Respiratory Tract and Sarcomas, Division of Thoracic Surgery, Department of Thoracic Surgery, Division of Pathology, Division of Thoracic Surgery, Division of Pathology and Laboratory Medicine, Department of Biomedical and Clinical Sciences ‘Luigi Sacco’, Università Cattolica del Sacro Cuore – Policlinico A. Gemelli, Rome, Italy
Search for other papers by G Pelosi in
Google Scholar
PubMed
. 1998 , Marchevsky et al . 2001 , Iyoda et al . 2007 , den Bakker et al . 2010 , Righi et al . 2010 , Ha et al . 2012 ). The clinical significance of distinguishing between high-grade LCNEC and SCLC is not clear due to the overlapping survival
Università Cattolica del Sacro Cuore, Rome, Italy
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy
Search for other papers by Guido Rindi in
Google Scholar
PubMed
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
-invasion-metastasis deposition. At the same time, prognosis depends on NEN cancer biology and displays a range of clinical behaviors from low to high grade malignancy. Indeed, a large fraction of well-differentiated NEN behave as low-grade malignant if not indolent. In fact, the
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Dermot O'Toole in
Google Scholar
PubMed
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Vinciane Rebours in
Google Scholar
PubMed
Search for other papers by Magali Zappa in
Google Scholar
PubMed
Search for other papers by Olivia Hentic in
Google Scholar
PubMed
Search for other papers by Pascal Hammel in
Google Scholar
PubMed
Search for other papers by Philippe Levy in
Google Scholar
PubMed
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Pierre Bedossa in
Google Scholar
PubMed
Search for other papers by Eric Raymond in
Google Scholar
PubMed
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
. Microvessel MVD ranged from 0 to 350 vessels/mm 2 (median: 100; mean: 126; Fig. 1 b); 42% had high expression. MVD was higher in tumors of grade G 2 /G 3 compared with G 1 tumors ( P =0.02). p53 The nuclear score ranged from 0 to 200 (median: 0; mean: 18
Search for other papers by Marijn A Vermeulen in
Google Scholar
PubMed
Search for other papers by Shusma C Doebar in
Google Scholar
PubMed
BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands
Search for other papers by Carolien H M van Deurzen in
Google Scholar
PubMed
Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
Search for other papers by John W M Martens in
Google Scholar
PubMed
Search for other papers by Paul J van Diest in
Google Scholar
PubMed
Search for other papers by Cathy B Moelans in
Google Scholar
PubMed
which low-grade DCIS progresses to low-grade IDC and high-grade DCIS to high-grade IDC. These parallel pathways have been postulated to have distinct genomic aberrations ( Hwang et al . 2004 , Moelans et al . 2010 a , Burger et al . 2013
Search for other papers by M Lacroix in
Google Scholar
PubMed
Search for other papers by R-A Toillon in
Google Scholar
PubMed
Search for other papers by G Leclercq in
Google Scholar
PubMed
expression or proliferation. A classification based on an ER-positive/ ER-negative or a low-grade/high-grade dichotomy hardly suffices to describe the complex spectrum of breast tumors; however, its simplicity will facilitate our main purpose: evaluating the
Search for other papers by Michail Kaklamanos in
Google Scholar
PubMed
Search for other papers by Ioannis Karoumpalis in
Google Scholar
PubMed
Search for other papers by Charitini Salla in
Google Scholar
PubMed
Search for other papers by Dimitrios Thomas in
Google Scholar
PubMed
Search for other papers by George Kanakis in
Google Scholar
PubMed
Search for other papers by Krystallenia Alexandraki in
Google Scholar
PubMed
Search for other papers by Stavros Sougioultzis in
Google Scholar
PubMed
Search for other papers by Evanthia Diakatou in
Google Scholar
PubMed
Search for other papers by George Kontogeorgos in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Dear Editor Although pancreatic neuroendocrine tumours (PETs) are rare, autopsy series have revealed a high incidence ranging from 0.8 to 10%, reflecting their relative lack of progression and low malignant potential ( Kaltsas et al . 2004
Search for other papers by O Hentic in
Google Scholar
PubMed
Search for other papers by P Hammel in
Google Scholar
PubMed
Search for other papers by A Couvelard in
Google Scholar
PubMed
Search for other papers by V Rebours in
Google Scholar
PubMed
Search for other papers by M Zappa in
Google Scholar
PubMed
Search for other papers by M Palazzo in
Google Scholar
PubMed
Search for other papers by F Maire in
Google Scholar
PubMed
Search for other papers by G Goujon in
Google Scholar
PubMed
Search for other papers by A Gillet in
Google Scholar
PubMed
Search for other papers by P Lévy in
Google Scholar
PubMed
Search for other papers by P Ruszniewski in
Google Scholar
PubMed
condition due to aggressive and diffuse disease. These tumors are characterized by aggressive histological features (high Ki-67 index, extensive necrosis, and nuclear atypia) and are classified as neuroendocrine carcinomas (NECs) grade 3 according to the new
Organisation for Oncology and Translational Research, Hong Kong SAR, China
UNIMED Medical Institute, Hong Kong SAR, China
Search for other papers by Louis W C Chow in
Google Scholar
PubMed
Search for other papers by Satoshi Morita in
Google Scholar
PubMed
Search for other papers by Christopher Y C Chow in
Google Scholar
PubMed
Search for other papers by Wai-Kuen Ng in
Google Scholar
PubMed
Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for other papers by Masakazu Toi in
Google Scholar
PubMed
Introduction The usefulness of endocrine therapy has been well demonstrated in the management of hormone-sensitive breast cancer ( Ellis et al. 2011 ). The neoadjuvant ACOSOG Z1031 trial showed a high clinical response rate of 63–75% in
Endocrinology Service, Human Oncology and Pathogenesis Program, Department of Pathology, Department of Medicine
Search for other papers by Mabel Ryder in
Google Scholar
PubMed
Search for other papers by Ronald A Ghossein in
Google Scholar
PubMed
Search for other papers by Julio C M Ricarte-Filho in
Google Scholar
PubMed
Endocrinology Service, Human Oncology and Pathogenesis Program, Department of Pathology, Department of Medicine
Search for other papers by Jeffrey A Knauf in
Google Scholar
PubMed
Endocrinology Service, Human Oncology and Pathogenesis Program, Department of Pathology, Department of Medicine
Search for other papers by James A Fagin in
Google Scholar
PubMed
each histological grade at low and high power magnifications. Figure 1 Immunostain for tumor-associated macrophages (TAM) markers in tissue microarrays. The signal is golden brown. (A) Very low density of CD68 + TAM per tissue core (0.28 mm 2 ) in well
Search for other papers by Pushpa Patel in
Google Scholar
PubMed
Search for other papers by Rowan Hardy in
Google Scholar
PubMed
Search for other papers by Vaiyapuri Sumathi in
Google Scholar
PubMed
Search for other papers by Gillian Bartle in
Google Scholar
PubMed
Search for other papers by Lars-Gunnar Kindblom in
Google Scholar
PubMed
Search for other papers by Robert Grimer in
Google Scholar
PubMed
Search for other papers by Iwona Bujalska in
Google Scholar
PubMed
Search for other papers by Paul M Stewart in
Google Scholar
PubMed
Search for other papers by Elizabeth Rabbitt in
Google Scholar
PubMed
Search for other papers by Neil J L Gittoes in
Google Scholar
PubMed
Search for other papers by Mark S Cooper in
Google Scholar
PubMed
). Most OSs are high grade and there are few morphological markers relating to long-term survival. Patients with metastases at presentation have a very poor outlook. For patients without clinically evident metastasis, the most important prognostic factor